Dr Sarah-Jane Schramm

Postdoctoral Research Associate
Medicine, Westmead Clinical School


Website Related website
Related website

Map

Biographical details

Between January 2009 and July 2012 I held a University of Sydney Postgraduate Award (UPA). During this time, I studied under the supervision of Professor Graham Mann in the Sydney Medical School (The University of Sydney) and the co-supervision of Professor Mark Wilkins at the School of Biotechnology and Biomolecular Sciences and the Systems Biology Initiative (University of New South Wales).

Over the final 2 years of my studies, I was permitted to divide my attendance between The University of Sydney and the University of New South Wales. This inimitable opportunity provided me with expert mentorship and research opportunities from different but increasingly related disciplines:melanoma and systems biology. My PhD thesis, ‘Molecular determinants of melanoma progression and prognosis’, was awarded in March 2014.

Since July 2012, I have been employed as a Post Doctoral Research Associate in the Sydney Medical School at The University of Sydney. In this role I continue to divide my time learning from, and collaborating across, different sub-disciplines including mathematics and statistics, bioinformatics, clinical oncology, and molecular biology.This approach provides me with direct access to the skills and infrastructure necessary to conduct research in the in the burgeoning and multi-disciplinary field of cancer systems biology.

Research interests

Molecular biomarkers of melanoma progression and prognosis

Cancer systems biology

Network biology

Integrative -omics

Bioinformatics

Network visualisation

Please check out my (more or less) fortnightly blog:The Inside Voice – reflections and ramblings of a newly minted post-doc. You can find it on the Sydney West Translational Cancer Research Centre knowledge portal.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Mann, G., Pupo, G., Campain, A., Carter, C., Schramm, S., Pianova, S., Gerega, S., Desilva, C., Lai, K., Wilmott, J., Hersey, P., Kefford, R., Thompson, J., Yang, J., Scolyer, R., et al (2013). BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. The Journal of Investigative Dermatology, 133(2), 509-517. [More Information]
  • Schramm, S., Li, S., Jayaswal, V., Fung, D., Campain, A., Pang, C., Scolyer, R., Yang, J., Mann, G., Wilkins, M. (2013). Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden. Pigment Cell and Melanoma Research, 26(5), 708-722. [More Information]
  • Schramm, S., Menzies, A., Mann, G. (2013). Molecular biomarkers of prognosis in melanoma: how far are we from the clinic? Melanoma Research, 23(6), 423-425. [More Information]
  • Schramm, S., Jayaswal, V., Goel, A., Li, S., Yang, J., Mann, G., Wilkins, M. (2013). Molecular interaction networks for the analysis of human disease: utility, limitations, and considerations. Proteomics, 13(23-24), 3393-3405. [More Information]
  • Jayaswal, V., Schramm, S., Mann, G., Wilkins, M., Yang, J. (2013). VAN: an R package for identifying biologically perturbed networks via differential variability analysis. BMC Research Notes, 6(1), 1-9. [More Information]
  • Schramm, S., Campain, A., Scolyer, R., Yang, J., Mann, G. (2012). Review and Cross-Validation of Gene Expression Signatures and Melanoma Prognosis. The Journal of Investigative Dermatology, 132(2), 274-283. [More Information]
  • Schramm, S., Mann, G. (2011). Melanoma Prognosis: A REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Molecular Cancer Therapeutics, 10(8), 1520-1528. [More Information]

2013

  • Mann, G., Pupo, G., Campain, A., Carter, C., Schramm, S., Pianova, S., Gerega, S., Desilva, C., Lai, K., Wilmott, J., Hersey, P., Kefford, R., Thompson, J., Yang, J., Scolyer, R., et al (2013). BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. The Journal of Investigative Dermatology, 133(2), 509-517. [More Information]
  • Schramm, S., Li, S., Jayaswal, V., Fung, D., Campain, A., Pang, C., Scolyer, R., Yang, J., Mann, G., Wilkins, M. (2013). Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden. Pigment Cell and Melanoma Research, 26(5), 708-722. [More Information]
  • Schramm, S., Menzies, A., Mann, G. (2013). Molecular biomarkers of prognosis in melanoma: how far are we from the clinic? Melanoma Research, 23(6), 423-425. [More Information]
  • Schramm, S., Jayaswal, V., Goel, A., Li, S., Yang, J., Mann, G., Wilkins, M. (2013). Molecular interaction networks for the analysis of human disease: utility, limitations, and considerations. Proteomics, 13(23-24), 3393-3405. [More Information]
  • Jayaswal, V., Schramm, S., Mann, G., Wilkins, M., Yang, J. (2013). VAN: an R package for identifying biologically perturbed networks via differential variability analysis. BMC Research Notes, 6(1), 1-9. [More Information]

2012

  • Schramm, S., Campain, A., Scolyer, R., Yang, J., Mann, G. (2012). Review and Cross-Validation of Gene Expression Signatures and Melanoma Prognosis. The Journal of Investigative Dermatology, 132(2), 274-283. [More Information]

2011

  • Schramm, S., Mann, G. (2011). Melanoma Prognosis: A REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Molecular Cancer Therapeutics, 10(8), 1520-1528. [More Information]

To update your profile click here. For support on your academic profile contact .